The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status-Reference-Cited by-同舟云学术

The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status

Published:2016-03-16 Issue:24 Volume:7 Page:35803-35812
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Bronte Giuseppe¹,Franchina Tindara²,Alù Massimiliano³,Sortino Giovanni¹,Celesia Claudia¹,Passiglia Francesco¹,Savio Giuseppina³,Laudani Agata³,Russo Alessandro²,Picone Antonio²,Rizzo Sergio¹,De Tursi Michele⁴,Gambale Elisabetta⁴,Bazan Viviana¹,Natoli Clara⁴,Blasi Livio³,Adamo Vincenzo²,Russo Antonio¹

Affiliation:

1. Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy

2. Medical Oncology Unit-AOOR Papardo-Piemonte, Messina and Department of Human Pathology, University of Messina, Messina, Italy

3. Medical Oncology Unit, A.R.N.A.S. Civico, Palermo, Italy

4. Department of Medical, Oral and Biotechnological Sciences, University “G. D'Annunzio”, Chieti, Italy

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An EGCG Derivative in Combination with Nimotuzumab for the Treatment of Wild-Type EGFR NSCLC;International Journal of Molecular Sciences;2023-09-13

2. An Immunomodulatory Gallotanin-Rich Fraction From Caesalpinia spinosa Enhances the Therapeutic Effect of Anti-PD-L1 in Melanoma;Frontiers in Immunology;2020-11-18

3. Liquid Biopsies;Technology in Practical Dermatology;2020

4. Erlotinib en 2e ou 3e ligne pour les cancers bronchiques non à petites cellules sans mutation de l’EGFR : données en vie réelle;Revue des Maladies Respiratoires;2019-06

5. Clinical efficacy of icotinib in patients with advanced nonsquamous non-small cell lung cancer with unknown EGFR mutation status that failed to respond to second-line chemotherapy;Annals of Translational Medicine;2018-10